Stock Price & Analysis

Sell FTRE stock as it shows significant weakness with a 7.02% drop in regular trading and multiple analyst downgrades. The stock is trading near oversold levels, but the bearish trend and negative sentiment suggest further downside risk.

Price Prediction for FTRE Stock in 2025

The price prediction for Fortrea Holdings Inc. (FTRE) stock in 2025 is expected to range between $10 and $12, with a potential upside to $15 if the company addresses its current challenges.

• Reasoning:
  • Analyst Consensus: The average analyst price target for FTRE is $13.40, but recent downward revisions suggest a more cautious outlook, with targets as low as $11.
  • Technical Analysis: The stock is currently oversold, with an RSI of 29.4, indicating potential short-term upside. However, the MACD remains bearish, and the stock is trading below its 50-day and 200-day moving averages.
  • Fundamental Challenges: Disappointing Q4 results, revenue void in 2025, and margin pressures due to older contracts are key concerns.
  • News Sentiment: Negative sentiment from the securities fraud investigation and weaker-than-expected financial performance have weighed on the stock.

{RATING:symbol=FTRE.O, type=0}

The S1 support level for FTRE Stock is $8.21 ,The R1 resistant level for FTRE Stock is $9.85.

As of the end of day on 2025-03-31, the price of FTRE Stock was $8.06.

The target price for FTRE Stock according to analyst rating is 12.00, with the highest price target at 15.00 and the lowest at 10.00. Analysts have a Hold rating on FTRE Stock overall.

The market cap of FTRE is $720.3M.

FTRE appears overvalued due to its high EV/EBITDA ratio of 52.9 and PS ratio of 1.16, indicating inflated valuation relative to earnings and revenue. The company has reported negative net income in recent quarters, with Q4 net income at -$61.2 million, raising profitability concerns. Analysts have lowered price targets, citing disappointing Q4 results and growth challenges, further signaling caution. The stock's poor price performance, down 18.8% on the day, aligns with these fundamentals. Overall, FTRE's valuation metrics and financial performance suggest it may be overvalued.

Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers’ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.

Price Prediction for FTRE Stock by 2030

Based on current trends and analysis, FTRE stock is predicted to reach $12 by 2030. This forecast considers the stock's oversold condition and potential rebound from its current low of $8.88, driven by possible improvements in its business operations and market sentiment. However, the prediction remains conservative due to ongoing investigations and financial challenges impacting the company's performance.

FTRE has a total of 18000 employees.